0.22  -0.006 (-2.61%)		01-14 09:31
Open: 0.2133 High: 0.22 Volume: 137,041		Pre. Close: 0.2259 Low: 0.2133 Market Cap: 5(M)

Short term
Mid term
Targets	6-month :	0.32	1-year :	0.37
Resists	First :	0.28	Second :	0.31
Pivot price	0.23
Supports	First :	0.21	Second :	0.18
MAs	MA(5) :	0.23	MA(20) :	0.24
	MA(100) :	0.32	MA(250) :	0.5
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	24.8	D(3) :	26.3
RSI	RSI(14): 35.8
52-week	High :	1.29	Low :	0.21

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ADIL ] has closed above bottom band by 19.8%. Bollinger Bands are 42% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.24 - 0.24	0.24 - 0.24
Low:	0.22 - 0.22	0.22 - 0.22
Close:	0.22 - 0.23	0.23 - 0.23

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Wed, 14 Jan 2026
Adial Pharmaceuticals Announces Publication of - GlobeNewswire

Wed, 14 Jan 2026
New patent aims to shield alcohol use disorder drug AD04 through 2045 - Stock Titan

Tue, 06 Jan 2026
Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year? - Yahoo Finance

Wed, 26 Nov 2025
Adial Pharmaceuticals (NASDAQ: ADIL) enters $2.86M inducement at $0.31 exercise price - Stock Titan

Fri, 14 Nov 2025
Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance

Thu, 09 Oct 2025
100% SNP concordance: Adial and Genomind validate cheek‑swab test for AD04; AG+ biomarker ~14% - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	27 (M)
Shares Float	24 (M)
Held by Insiders	2.2 (%)
Held by Institutions	3.9 (%)
Shares Short	407 (K)
Shares Short P.Month	419 (K)

EPS	-0.61
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.18
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-79.4 %
Return on Equity (ttm)	-155.1 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.3
Qtrly Earnings Growth	0 %
Operating Cash Flow	-7 (M)
Levered Free Cash Flow	-4 (M)

PE Ratio	-0.38
PEG Ratio	0
Price to Book value	1.18
Price to Sales	0
Price to Cash Flow	-0.91

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.